Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Prescription medicine

Birch triterpenes

Official FDA data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the drug label, the NDC Directory, Drugs@FDA, recall reports and the drug shortage list. Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

Quick answers

What is Birch triterpenes used for?
The FDA-approved label (Filsuvez, Chiesi USA, Inc., July 24, 2026) says: “FILSUVEZ is indicated for the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in adult and pediatric patients 6 months of age and older. FILSUVEZ topical gel is indicated for the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa in adult and pediatric patients 6 months of age and older.” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Does Birch triterpenes have a boxed warning?
No. None of the 2 FDA labels we found for this medicine has a boxed warning.
Is there a shortage of Birch triterpenes?
No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
Has Birch triterpenes been recalled?
No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
Who makes Birch triterpenes?
2 companies list prescription products of Birch triterpenes in the FDA NDC Directory, including Chiesi USA, Inc. and Amryt Pharmaceuticals DAC.

What Birch triterpenes is used for

Quoted from the “Indications and Usage” section of the FDA-approved label.

FILSUVEZ is indicated for the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in adult and pediatric patients 6 months of age and older. FILSUVEZ topical gel is indicated for the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa in adult and pediatric patients 6 months of age and older.

— FDA label: Filsuvez, Chiesi USA, Inc., effective July 24, 2026. Read the full label on DailyMed →

The FDA has 2 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

Boxed warning

A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.

The label quoted above has no boxed warning.

0 of 2 FDA labels for this medicine have a boxed warning.

Forms and how it is given

Dosage formsGel
RouteTopical
Prescription products2 in the FDA NDC Directory
Brand namesFilsuvez

Companies that list this medicine

Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.

FDA approval history

  • NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
Brand and biologic applications
ApplicationSponsorApprovedLater changes approved
NDA215064
FILSUVEZ
ChiesiDecember 18, 2023 —

Shortage status

The FDA drug shortage list does not show these products.

FDA Drug Shortages database →

Recalls

No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.

Official identifiers

RxCUI (RxNorm)2675587, 2675592
SPL set ID of the quoted label32ba9194-734c-47d4-84e1-b21e28a85ec5
FDA labels (SPL)2
FDA applicationsNDA215064
Active ingredients (FDA)BIRCH TRITERPENES

Sources

  1. FDA-approved label on DailyMed (National Library of Medicine) — Filsuvez, Chiesi USA, Inc., effective July 24, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
  2. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  3. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  4. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
  5. Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026

openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →

Report an error → · Information for medicine makers